JAK2 Inhibitors RUXOLITINIB in Patients With High or Intermediate Risk Primary or Secondary Myelofibrosis Eligible for Allogeneic Stem Cell Transplantation: a Prospective Multicentric Phase II Study
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 24 Jul 2018
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Myelofibrosis
- Focus Therapeutic Use
- 26 Apr 2018 Planned primary completion date changed from 1 Aug 2015 to 1 May 2018.
- 20 Mar 2017 Planned End Date changed from 1 Oct 2017 to 1 Mar 2019.
- 20 Mar 2017 Status changed from recruiting to active, no longer recruiting.